{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-021099","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.263560+00:00","generated_at":"2026-06-05T10:30:36.785083+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cytokinetics reports Q4 2023 net loss of $1.38/share; positive SEQUOIA-HCM results, NDA planned for Q3 2024","bullets":["Net loss Q4 2023: $136.9M ($1.38/share); full year net loss $526.2M ($5.45/share).","Year-end cash $655.4M; additional ~$83M raised via ATM in early 2024; ~2-year cash runway.","SEQUOIA-HCM showed aficamten improved pVO2 by 1.74 mL/kg/min (p=0.000002) vs placebo; all 10 secondary endpoints met.","Plans to submit NDA to FDA in Q3 2024 and MAA to EMA in Q4 2024 for aficamten.","2024 guidance: revenue $3-5M, operating expenses $420-450M, net cash utilization ~$390-420M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-021099","json":"https://secwatch.observer/filing/0000950170-24-021099.json","markdown":"https://secwatch.observer/filing/0000950170-24-021099.md","text":"https://secwatch.observer/filing/0000950170-24-021099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024021099/0000950170-24-021099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024021099/cytk-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T10:30:36.785083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"714b755e9b8471338b5753726f52803828ea011f","claim":"CYTOKINETICS INC reported the fourth quarter and full year 2023 results: net income Net loss for the fourth quarter was $136.9 million or $1.38 per share and the net loss for the year 2023 was $526.2 mill.","evidence_excerpt":"On February 27, 2024, Cytokinetics, Incorporated announced its financial results for the fourth quarter and for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017024021099/0000950170-24-021099-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2023"},{"label":"Net income","value":"Net loss for the fourth quarter was $136.9 million or $1.38 per share and the net loss for the year 2023 was $526.2 mill"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}